Adult vaccination for pneumococcal disease: a comparison of the national guidelines in Europe
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
ID 4501678
Author(s) Bonnave, C.; Mertens, D.; Peetermans, W.; Cobbaert, K.; Ghesquiere, B.; Deschodt, M.; Flamaing, J.
Author(s) at UniBasel Deschodt, Mieke
Year 2019
Title Adult vaccination for pneumococcal disease: a comparison of the national guidelines in Europe
Journal European Journal of Clinical Microbiology & Infectious Diseases
Volume 38
Number 4
Pages / Article-Number 785-791
Keywords Pneumococcal vaccination; Adults; Europe; Recommendations; PCV13; PPV23
Mesh terms Science & TechnologyLife Sciences & BiomedicineInfectious DiseasesMicrobiologyInfectious DiseasesMicrobiology
Abstract Pneumococcal disease constitutes a major global health problem. Adults aged over 50years and younger adults with specific chronic health conditions are at risk for invasive pneumococcal disease, associated with substantial morbidity and mortality. In Europe, two vaccine types are used in adults for pneumococcal immunization: pneumococcal polysaccharide vaccine (PPV23) and pneumococcal conjugate vaccine (PCV13). To provide an overview and to compare the national guidelines for pneumococcal immunization for adults in Europe. In November 2016, national guidelines on pneumococcal vaccination for adults of 31 European countries were obtained by Google search, the website of European Centre for Disease Prevention and Control, and contacting public health officials. In our analysis, we distinguished between age-based and risk-based guidelines. In October 2017, we used the same method to retrieve guideline updates. We observed great variability regarding age, risk groups, vaccine type, and use of boosters. In age-based guidelines, vaccination is mostly recommended in adults aged over 65years using PPV23. Boosters are generally not recommended. An upper age limit for vaccination is reported in three countries. In the immunocompromised population, vaccination with both vaccines and administration of a booster is mostly recommended. In the population with chronic health conditions, there is more heterogeneity according vaccine type, sequence, and administration of boosters. Asplenia is the only comorbidity for which all countries recommend vaccination. The great variability in European pneumococcal vaccination guidelines warrants European unification of the guidelines for better control of pneumococcal disease.
Publisher Springer
ISSN/ISBN 0934-9723
Full Text on edoc Available
Digital Object Identifier DOI 10.1007/s10096-019-03485-3
PubMed ID
ISI-Number 000461781100023
Document type (ISI) Journal Article

MCSS v5.8 PRO. 0.450 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |